23 C
New York
Sunday, June 14, 2026

Tag: vaccines

newssourceFORcompanyinformationcontent1marketreleases

Novo Nordisk Foundation and University of Copenhagen announce USD 109 million grant to new Danish research centre to make designed proteins with vast potential

COPENHAGEN, Denmark, June 25, 2025 /PRNewswire/ -- Designed proteins are anticipated to have groundbreaking impact on a range of issues from treating disease to...

Novo Nordisk Foundation and University of Copenhagen announce USD 109 million grant to new Danish research centre to make designed proteins with vast potential

COPENHAGEN, Denmark, June 25, 2025 /PRNewswire/ -- Designed proteins are anticipated to have groundbreaking impact on a range of issues from treating disease to...

Health and Wellness Market Size Worth USD 11 Trillion by 2034

The health and wellness market size is expected to be worth over USD 11 trillion by 2034, increasing from USD 6.57 trillion in 2024, with a CAGR of 5.50%. The market of health and wellness is driven by rising health awareness, an aging population, technological advancements, growing health consciousness, and supportive government initiatives. 
The health and wellness market size is expected to be worth over USD 11 trillion by 2034, increasing from USD 6.57 trillion in 2024, with a CAGR of 5.50%. The market of health and wellness is driven by rising health awareness, an aging population, technological advancements, growing health consciousness, and supportive government initiatives.

Kicking Off Today! Process Intensified. Drug Manufacturing Accelerated. The Sartorius PI Forum opens in Boston — shaping biomanufacturing’s future

Sartorius launches a premier industry event focused on process intensification (PI) for protein therapeutics and emerging modalities.Forum features expert-led sessions, hands-on workshops, and live...

Stewart Investors Identifies Six Global Companies Advancing Health Beyond Pharma

Brown & Brown, Cintas Corporation, Haleon, Linde, Raia Drogasil and Veeva Systems are making access to health and hygiene more equitable. EDINBURGH, Scotland, June...

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)

SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Pharmaceutical Membrane Filters Market Size to Surpass USD 20.05 Billion by 2031, at 13.1% CAGR: The Insight Partners

NEW YORK, June 19, 2025 /PRNewswire/ -- According to a new, comprehensive report from The Insight Partners, the pharmaceutical membrane filters market is growing...

The Department of Health – Abu Dhabi and Sanofi Forge Strategic Alliance to Accelerate the Development of New Global Vaccines in Abu Dhabi

On the sidelines of a high-level US visit focused on healthcare innovation ABU DHABI, UAE, June 19, 2025 /PRNewswire/ -- The Department of Health – Abu...

Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans

HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased...

Oligonucleotide Synthesis Market is expected to generate a revenue of USD 5.75 Billion by 2031, Globally, at 10.49% CAGR: Verified Market Research®

The Oligonucleotide Synthesis Market is poised for robust growth, fueled by advancements in personalized medicine, molecular diagnostics, and genomics research. However, high production costs, regulatory...

Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million

COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsVaccines

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers